A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer
Science Advances · 2026
DOI: 10.1126/sciadv.aea6734 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Tenzin Ngodup und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Plasminogen Activator Inhibitor 1, Tissue Plasminogen Activator. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a dense desmoplastic stroma and an immunosuppressive tumor microenvironment that contribute to therapeutic resistance. Here, we identify plasminogen activator inhibitor 1 (PAI1) as a stroma-derived mediator of immune evasion and tumor progression in PDAC. PAI1 is predominantly produced and secreted by cancer-associated fibroblasts, and its genetic ablation in the stromal compartment impairs tumor growth. Mechanistically, hypoxia induces PAI1 expression in fibroblasts, which in turn shifts macrophages toward immunosuppressive phenotypes and suppresses CD8 + T cell infiltration and function. We further show that tissue plasminogen activator (tPA), a direct PAI1 target, is also secreted by fibroblasts and supports antitumor CD8 + T cell responses. Notably, elimination of stromal tPA promotes immunosuppressive macrophage phenotypes, reduces CD8 + T cell infiltration, and accelerates PDAC progression. These findings define a previously unrecognized PAI1-tPA regulatory axis within the tumor stroma that modulates antitumor immunity. Targeting this pathway may provide a therapeutic opportunity to overcome stroma-driven immune suppression in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA.
- Program in Immunology, University of Michigan, Ann Arbor, MI 48109, USA.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Tenzin Ngodup, Brynn Elson, Ashley M Mello, Sean Hannifin, Yaqing Zhang, Jiaqi Shi, Yatrik M Shah, Daniel A Lawrence, Marina Pasca di Magliano, Kyoung Eun Lee
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Rogel Cancer Center, University of Michigan
Zitieren
APA
Ngodup, T., Elson, B., Mello, A. M., Hannifin, S., Liu, M., Zhang, Y., Shi, J., Shah, Y. M., Lawrence, D. A., di Magliano, M. P., & Lee, K. E. (2026). A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer. Science Advances. https://doi.org/10.1126/sciadv.aea6734
Vancouver
Ngodup T, Elson B, Mello AM, Hannifin S, Liu M, Zhang Y, et al. A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer. Science Advances. 2026. doi:10.1126/sciadv.aea6734
BibTeX
@article{Ngodup2026,
author = {Ngodup, Tenzin and Elson, Brynn and Mello, Ashley M and Hannifin, Sean and Liu, Miranda and Zhang, Yaqing and Shi, Jiaqi and Shah, Yatrik M and Lawrence, Daniel A and di Magliano, Marina Pasca and Lee, Kyoung Eun},
title = {A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aea6734}
}
EUVIMED